Equities

Flerie AB

Flerie AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)46.18
  • Today's Change0.88 / 1.94%
  • Shares traded27.07k
  • 1 Year change+111.83%
  • Beta-0.0060
Data delayed at least 15 minutes, as of Nov 25 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Flerie AB has grown net income from a loss of -100.33m to a smaller loss of -95.27m primarily through revenue growth (0.00 to 97.51m). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales , the -- growth in revenues contributed enough to still see net income improve.
Gross margin-92,017.00%
Net profit margin-269,618.00%
Operating margin-298,021.00%
Return on assets-11.53%
Return on equity-11.70%
Return on investment-11.69%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Flerie AB fell by 50.66m. However, Cash Flow from Investing was flat, indicating that little new money was committed to growth. In addition the company used 37.98m for operations while cash used for financing totalled 1.03m.
Cash flow per share-5.08
Price/Cash flow per share--
Book value per share54.59
Tangible book value per share54.59
More ▼

Balance sheet in SEKView more

Flerie AB has little financial risk as the capital structure does not rely on leverage.
Current ratio45.89
Quick ratio--
Total debt/total equity0.0002
Total debt/total capital0.0002
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.